Contraindications: Contraindicated in individuals with prostate carcinoma, breast carcinoma, or severe hepatic impairment. Not for use in women of childbearing potential. Absolutely contraindicated in combination with other 19-nor anabolic steroids (e.g., Trenbolone, NPP used concurrently) without endocrinological supervision and active prolactin monitoring. Do not co-administer with 5α-reductase inhibitors — this combination produces paradoxical androgenic amplification specific to Nandrolone's metabolic pathway.
Side Effects: Prolactin elevation is the primary class-specific risk and is compounded by unfavourable stack choices; monitor serum prolactin at cycle midpoint. Suppression of endogenous testosterone production is expected and dose-dependent. Androgenic effects — acne, scalp thinning — are dose- and genotype-dependent. Water retention is possible at doses above 300 mg/week. Cardiovascular markers (haematocrit, lipid panel) warrant monitoring across all injectable androgen cycles.
Monitoring: Baseline bloodwork prior to cycle commencement should include LH, FSH, total testosterone, prolactin, estradiol, haematocrit, and lipid panel. Repeat at week 4–6 and again at cycle end. If Nandrolone Decanoate is combined with any compound carrying progestogenic activity, prolactin testing frequency should increase to every 4 weeks. HPLC-verified batch documentation from Omega Meds supports dose confidence but does not replace individual hormonal monitoring.
PCT: Begin PCT no earlier than 3 weeks after the final Nandrolone Decanoate injection to allow plasma concentrations to decline sufficiently. Standard PCT protocols using Clomiphene citrate (50 mg/day for 4 weeks) or Tamoxifen (20 mg/day for 6 weeks) apply. If elevated prolactin was detected during cycle, cabergoline continued into early PCT at 0.25 mg twice weekly may be warranted under medical guidance.